Targeting Profibrotic Macrophages Using Mir-33 Inhibitors, a Novel Therapeutic Approach for Pulmonary Fibrosis
Target Site Blocker (TSB) of the IL-17A-miR466I-3p iInteraction Prevents Progressive and Relapsing Remitting EAE
